{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:55:42Z","timestamp":1790398542377,"version":"4.1.0"},"reference-count":195,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"am","delay-in-days":258,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AG067329"],"award-info":[{"award-number":["AG067329"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AG052986"],"award-info":[{"award-number":["AG052986"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AG052005"],"award-info":[{"award-number":["AG052005"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AG051459"],"award-info":[{"award-number":["AG051459"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ageing Research Reviews"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.arr.2021.101318","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T20:16:33Z","timestamp":1615320993000},"page":"101318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"C","title":["Therapy for Alzheimer\u2019s disease: Missing targets and functional markers?"],"prefix":"10.1016","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7354-6846","authenticated-orcid":false,"given":"Milan","family":"Stoiljkovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamas L.","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5379-8576","authenticated-orcid":false,"given":"Mih\u00e1ly","family":"Haj\u00f3s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arr.2021.101318_bib0005","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrn3024","article-title":"Not(ch) just development: notch signalling in the adult brain","volume":"12","author":"Ables","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.arr.2021.101318_bib0010","doi-asserted-by":"crossref","first-page":"9677","DOI":"10.1523\/JNEUROSCI.4742-11.2012","article-title":"An effector-reduced anti-beta-amyloid (Abeta) antibody with unique Abeta binding properties promotes neuroprotection and glial engulfment of Abeta","volume":"32","author":"Adolfsson","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2021.101318_bib0015","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3233\/JAD-150277","article-title":"Selective brain-targeted antagonism of p38 MAPKalpha reduces hippocampal IL-1beta levels and improves morris water maze performance in aged rats","volume":"48","author":"Alam","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101318_bib0020","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000051232","article-title":"Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in alzheimer patients","volume":"12","author":"Almkvist","year":"2001","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.arr.2021.101318_bib0025","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/alz.12068","article-title":"2020 alzheimer\u2019s disease facts and figures","volume":"16","author":"Alzheimer\u2019s Association","year":"2020","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2021.101318_bib0030","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrneurol.2017.185","article-title":"Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums","volume":"14","author":"Arnold","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.arr.2021.101318_bib0035","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.neurobiolaging.2019.09.008","article-title":"What electrophysiology tells us about Alzheimer\u2019s disease: a window into the synchronization and connectivity of brain neurons","volume":"85","author":"Babiloni","year":"2020","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2021.101318_bib0040","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.brs.2020.09.010","article-title":"Enhancing cognitive training effects in Alzheimer\u2019s disease: rTMS as an add-on treatment","volume":"13","author":"Bagattini","year":"2020","journal-title":"Brain Stimul"},{"key":"10.1016\/j.arr.2021.101318_bib0045","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/583931","article-title":"Precuneus and cingulate cortex atrophy and hypometabolism in patients with alzheimer\u2019s disease and mild cognitive impairment: MRI and (18)F-FDG PET quantitative analysis using FreeSurfer","volume":"2015","author":"Bailly","year":"2015","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.arr.2021.101318_bib0050","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.tins.2016.01.003","article-title":"BACE1 physiological functions May limit its use as therapeutic target for alzheimer\u2019s disease","volume":"39","author":"Barao","year":"2016","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.arr.2021.101318_bib0055","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jalz.2016.07.005","article-title":"The DIAN-TU next generation alzheimer\u2019s prevention trial: adaptive design and disease progression model","volume":"13","author":"Bateman","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2021.101318_bib0060","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/j.celrep.2016.01.076","article-title":"Specific inhibition of beta-secretase processing of the alzheimer disease amyloid precursor protein","volume":"14","author":"Ben Halima","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.arr.2021.101318_bib0065","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jama.2017.19700","article-title":"Lack of benefit with idalopirdine for alzheimer disease: another therapeutic failure in a complex disease process","volume":"319","author":"Bennett","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.arr.2021.101318_bib0070","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/B978-0-12-385883-2.00008-4","article-title":"The genetics of alzheimer\u2019s disease","volume":"107","author":"Bertram","year":"2012","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.arr.2021.101318_bib0075","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.bcp.2017.12.008","article-title":"The wonderland of neuronal nicotinic acetylcholine receptors","volume":"151","author":"Bertrand","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.arr.2021.101318_bib0080","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1148\/radiol.12120928","article-title":"Cerebral blood flow measured with 3D pseudocontinuous arterial spin-labeling MR imaging in alzheimer disease and mild cognitive impairment: a marker for disease severity","volume":"267","author":"Binnewijzend","year":"2013","journal-title":"Radiology"},{"key":"10.1016\/j.arr.2021.101318_bib0085","article-title":"Donepezil for dementia due to Alzheimer\u2019s disease","volume":"6","author":"Birks","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.arr.2021.101318_bib0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104707","article-title":"Advances and considerations in AD tau-targeted immunotherapy","volume":"134","author":"Bittar","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.arr.2021.101318_bib0095","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/bs.pmbts.2019.07.006","article-title":"Fluid biomarker-based molecular phenotyping of Alzheimer\u2019s disease patients in research and clinical settings","volume":"168","author":"Blennow","year":"2019","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.arr.2021.101318_bib0100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3233\/JAD-2011-110977","article-title":"Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta","volume":"28","author":"Bohrmann","year":"2012","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101318_bib0105","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2314-9","article-title":"Variability in the analysis of a single neuroimaging dataset by many teams","author":"Botvinik-Nezer","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.arr.2021.101318_bib0110","doi-asserted-by":"crossref","first-page":"7389","DOI":"10.1021\/acs.jmedchem.5b01960","article-title":"Gamma secretase modulators: New alzheimer\u2019s drugs on the horizon?","volume":"59","author":"Bursavich","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.arr.2021.101318_bib0115","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/WNF.0b013e318279bcfa","article-title":"Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease","volume":"36","author":"Burstein","year":"2013","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.arr.2021.101318_bib0120","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/14728214.2017.1293651","article-title":"Emerging chemical therapies targeting 5-hydroxytryptamine in the treatment of Alzheimer\u2019s disease","volume":"22","author":"Calhoun","year":"2017","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.arr.2021.101318_bib0125","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13195-018-0347-1","article-title":"Effects of pharmacological and nonpharmacological treatments on brain functional magnetic resonance imaging in Alzheimer\u2019s disease and mild cognitive impairment: a critical review","volume":"10","author":"Canu","year":"2018","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.arr.2021.101318_bib0130","first-page":"202","article-title":"Reversible and species-specific depigmentation effects of AZD3293, a BACE inhibitor for the treatment of alzheimer\u2019s disease, are related to BACE2 inhibition and confined to epidermis and hair","volume":"3","author":"Cebers","year":"2016","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.arr.2021.101318_bib0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2019.08.020","article-title":"A systematic review and meta-analysis of rTMS effects on cognitive enhancement in mild cognitive impairment and Alzheimer\u2019s disease","volume":"86","author":"Chou","year":"2019","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2021.101318_bib0140","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1186\/s12877-020-01926-9","article-title":"The role of physical and cognitive function in performance of activities of daily living in patients with mild-to-moderate Alzheimer\u2019s disease - a cross-sectional study","volume":"20","author":"Clemmensen","year":"2020","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.arr.2021.101318_bib0145","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","article-title":"Tau-targeting therapies for Alzheimer disease","volume":"14","author":"Congdon","year":"2018","journal-title":"Nat. Rev. Neurol"},{"key":"10.1016\/j.arr.2021.101318_bib0150","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1161\/CIRCRESAHA.118.313477","article-title":"Angiotensin II- and alzheimer-type cardiovascular aging","volume":"123","author":"Cooper","year":"2018","journal-title":"Circ. Res."},{"key":"10.1016\/j.arr.2021.101318_bib0155","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1001\/jamaneurol.2015.0607","article-title":"Targeting prodromal alzheimer disease with avagacestat: a randomized clinical trial","volume":"72","author":"Coric","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2021.101318_bib0160","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13195-019-0579-8","article-title":"Effector function of anti-pyroglutamate-3 Abeta antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer\u2019s-like mice","volume":"12","author":"Crehan","year":"2020","journal-title":"Alzheimers Res. Ther"},{"key":"10.1016\/j.arr.2021.101318_bib0165","doi-asserted-by":"crossref","first-page":"7209","DOI":"10.1021\/bi301137h","article-title":"BMS-708,163 targets presenilin and lacks notch-sparing activity","volume":"51","author":"Crump","year":"2012","journal-title":"Biochemistry"},{"key":"10.1016\/j.arr.2021.101318_bib0170","doi-asserted-by":"crossref","first-page":"e1889","DOI":"10.1212\/WNL.0000000000005550","article-title":"ABBY: a phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease","volume":"90","author":"Cummings","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2021.101318_bib0175","doi-asserted-by":"crossref","first-page":"157","DOI":"10.14283\/jpad.2019.14","article-title":"Anti-tau trials for Alzheimer\u2019s disease: a report from the EU\/US\/CTAD task force","volume":"6","author":"Cummings","year":"2019","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.arr.2021.101318_bib0180","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11920-019-1058-4","article-title":"Advances in management of neuropsychiatric syndromes in neurodegenerative diseases","volume":"21","author":"Cummings","year":"2019","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.arr.2021.101318_bib0185","article-title":"Alzheimer\u2019s disease drug development pipeline: 2020","volume":"6","author":"Cummings","year":"2020","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.arr.2021.101318_bib0190","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13024-016-0115-2","article-title":"Immunotherapy targeting pyroglutamate-3 Abeta: prospects and challenges","volume":"11","author":"Cynis","year":"2016","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.arr.2021.101318_bib0195","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40263-019-00613-7","article-title":"A close look at BACE1 inhibitors for Alzheimer\u2019s disease treatment","volume":"33","author":"Das","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.arr.2021.101318_bib0200","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1523\/JNEUROSCI.4672-12.2013","article-title":"Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer\u2019s disease: prelude to a clinical trial","volume":"33","author":"Davtyan","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2021.101318_bib0205","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.neuropharm.2017.07.010","article-title":"Antagonism of the 5-HT6 receptor - preclinical rationale for the treatment of Alzheimer\u2019s disease","volume":"125","author":"de Jong","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.arr.2021.101318_bib0210","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0896-6273(03)00205-8","article-title":"Aph-1, Pen-2, and nicastrin with presenilin generate an active gamma-secretase complex","volume":"38","author":"De Strooper","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.arr.2021.101318_bib0215","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrneurol.2009.218","article-title":"The secretases: enzymes with therapeutic potential in Alzheimer disease","volume":"6","author":"De Strooper","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.arr.2021.101318_bib0220","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","article-title":"A plaque-specific antibody clears existing beta-amyloid plaques in Alzheimer\u2019s disease mice","volume":"76","author":"Demattos","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.arr.2021.101318_bib0225","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aau3333","article-title":"Porphyromonas gingivalis in Alzheimer\u2019s disease brains: evidence for disease causation and treatment with small-molecule inhibitors","volume":"5","author":"Dominy","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.arr.2021.101318_bib0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0205704","article-title":"Repetitive transcranial magnetic stimulation for the treatment of Alzheimer\u2019s disease: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Dong","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.arr.2021.101318_bib0235","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease","volume":"369","author":"Doody","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2021.101318_bib0240","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Doody","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2021.101318_bib0245","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00401-016-1662-x","article-title":"Alzheimer\u2019s disease: experimental models and reality","volume":"133","author":"Drummond","year":"2017","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.arr.2021.101318_bib0250","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","article-title":"Randomized trial of verubecestat for prodromal Alzheimer\u2019s disease","volume":"380","author":"Egan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2021.101318_bib0255","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1172\/JCI18162","article-title":"NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo","volume":"112","author":"Eriksen","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.arr.2021.101318_bib0260","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41467-017-02753-0","article-title":"Closed-loop stimulation of temporal cortex rescues functional networks and improves memory","volume":"9","author":"Ezzyat","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.arr.2021.101318_bib0265","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jalz.2011.09.224","article-title":"Safety and biomarker effects of solanezumab in patients with Alzheimer\u2019s disease","volume":"8","author":"Farlow","year":"2012","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2021.101318_bib0270","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13195-015-0108-3","article-title":"Long-term treatment with active Abeta immunotherapy with CAD106 in mild Alzheimer\u2019s disease","volume":"7","author":"Farlow","year":"2015","journal-title":"Alzheimers Res. Ther"},{"key":"10.1016\/j.arr.2021.101318_bib0275","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000113712","article-title":"M1 muscarinic agonists target major hallmarks of alzheimer\u2019s disease--the pivotal role of brain M1 receptors","volume":"5","author":"Fisher","year":"2008","journal-title":"Neurodegener Dis."},{"key":"10.1016\/j.arr.2021.101318_bib0280","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3389\/fnagi.2018.00293","article-title":"A 16-week aerobic exercise intervention does not affect hippocampal volume and cortical thickness in mild to moderate alzheimer\u2019s disease","volume":"10","author":"Frederiksen","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.arr.2021.101318_bib0285","article-title":"Computerised cognitive training for 12 or more weeks for maintaining cognitive function in cognitively healthy people in late life","volume":"2","author":"Gates","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.arr.2021.101318_bib0290","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2021.101318_bib0295","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1016\/j.bbamem.2013.06.005","article-title":"gamma-secretase inhibitors and modulators","volume":"1828","author":"Golde","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.arr.2021.101318_bib0300","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2174\/1567205013666160930113907","article-title":"Therapeutic noninvasive brain stimulation in alzheimer\u2019s disease","volume":"14","author":"Gonsalvez","year":"2017","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.arr.2021.101318_bib0305","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13024-018-0298-9","article-title":"New insights into the role of TREM2 in Alzheimer\u2019s disease","volume":"13","author":"Gratuze","year":"2018","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.arr.2021.101318_bib0310","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1001\/jama.2009.1866","article-title":"Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial","volume":"302","author":"Green","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.arr.2021.101318_bib0315","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev-med-060619-022857","article-title":"Synchronizing brain rhythms to improve cognition","volume":"72","author":"Grover","year":"2021","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.arr.2021.101318_bib0320","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.trci.2018.11.001","article-title":"A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer\u2019s disease","volume":"5","author":"Grundman","year":"2019","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.arr.2021.101318_bib0325","series-title":"Sensory-Evoked Steady-State Oscillations in Alzheimer\u2019s Disease Patients: Biomarker and Therapeutic Applications American Clinical Neurophysiology Society (ACNS) Annual Meeting and Courses 2020","author":"Haj\u00f3s","year":"2020"},{"key":"10.1016\/j.arr.2021.101318_bib0330","first-page":"108081","article-title":"Future avenues for Alzheimer\u2019s disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery","author":"Hampel","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.arr.2021.101318_bib0335","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of alzheimer\u2019s disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.arr.2021.101318_bib0340","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1743-7075-6-31","article-title":"Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer\u2019s disease: a randomized, double-blind, placebo-controlled, multicenter trial","volume":"6","author":"Henderson","year":"2009","journal-title":"Nutr Metab (Lond)"},{"key":"10.1016\/j.arr.2021.101318_bib0345","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMc1813435","article-title":"Preliminary results of a trial of atabecestat in preclinical alzheimer\u2019s disease","volume":"380","author":"Henley","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2021.101318_bib0350","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1080\/14760584.2018.1500905","article-title":"Recent advancements toward therapeutic vaccines against Alzheimer\u2019s disease","volume":"17","author":"Herline","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.arr.2021.101318_bib0355","doi-asserted-by":"crossref","first-page":"38408","DOI":"10.1074\/jbc.M112.415505","article-title":"Beta-site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1)-deficient mice exhibit a close homolog of L1 (CHL1) loss-of-function phenotype involving axon guidance defects","volume":"287","author":"Hitt","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.arr.2021.101318_bib0360","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to alzheimer\u2019s disease","volume":"378","author":"Honig","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2021.101318_bib0365","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1074\/jbc.M114.586602","article-title":"A Food and Drug Administration-approved asthma therapeutic agent impacts amyloid beta in the brain in a transgenic model of Alzheimer disease","volume":"290","author":"Hori","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.arr.2021.101318_bib0370","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2741\/4587","article-title":"EEG and ERP biomarkers of Alzheimer\u2019s disease: a critical review","volume":"23","author":"Horvath","year":"2018","journal-title":"Front Biosci. (Landmark Ed)"},{"key":"10.1016\/j.arr.2021.101318_bib0375","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/13543784.2019.1619694","article-title":"Tau immunotherapies for Alzheimer\u2019s disease","volume":"28","author":"Hoskin","year":"2019","journal-title":"Expert Opin. Investig Drugs"},{"key":"10.1016\/j.arr.2021.101318_bib0380","article-title":"Questions EMERGE as Biogen claims aducanumab turnaround","author":"Howard","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.arr.2021.101318_bib0385","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3389\/fnagi.2017.00292","article-title":"Low-frequency repetitive transcranial magnetic stimulation ameliorates cognitive function and synaptic plasticity in APP23\/PS45 mouse model of alzheimer\u2019s disease","volume":"9","author":"Huang","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.arr.2021.101318_bib0390","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nature20587","article-title":"Gamma frequency entrainment attenuates amyloid load and modifies microglia","volume":"540","author":"Iaccarino","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.arr.2021.101318_bib0395","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3233\/JAD-2009-1092","article-title":"Why did tarenflurbil fail in alzheimer\u2019s disease?","volume":"17","author":"Imbimbo","year":"2009","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101318_bib0400","doi-asserted-by":"crossref","first-page":"P1622","DOI":"10.1016\/j.jalz.2018.07.212","article-title":"TRAILBLAZER-ALZ (NCT03367403): a phase 2 disease-modification combination therapy trial targeting multiple mechanisms of action along the amyloid pathway","volume":"14","author":"Irizarry","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2021.101318_bib0405","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nrn2967","article-title":"Amyloid-beta and tau--a toxic pas de deux in Alzheimer\u2019s disease","volume":"12","author":"Ittner","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.arr.2021.101318_bib0410","article-title":"Alzheimer\u2019s therapeutics targeting amyloid beta 1-42 oligomers II: sigma-2\/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity","volume":"9","author":"Izzo","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.arr.2021.101318_bib0415","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","article-title":"Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers","volume":"12","author":"Jack","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.arr.2021.101318_bib0420","article-title":"Modifying the progression of Alzheimer\u2019s and Parkinson\u2019s disease with deep brain stimulation","author":"Jakobs","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.arr.2021.101318_bib0425","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3233\/JAD-200931","article-title":"Memory-related frontal brainwaves predict transition to mild cognitive impairment in healthy older individuals Five years Before diagnosis","volume":"79","author":"Jiang","year":"2021","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101318_bib0430","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41593-018-0238-6","article-title":"Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases","volume":"21","author":"Jucker","year":"2018","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.arr.2021.101318_bib0435","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1517\/14712598.2010.493872","article-title":"Bapineuzumab","volume":"10","author":"Kerchner","year":"2010","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.arr.2021.101318_bib0440","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hbm.24894","article-title":"The heterogeneous functional architecture of the posteromedial cortex is associated with selective functional connectivity differences in Alzheimer\u2019s disease","volume":"41","author":"Khan","year":"2020","journal-title":"Hum. Brain Mapp."},{"key":"10.1016\/j.arr.2021.101318_bib0445","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/13543784.2018.1483334","article-title":"The role of 5 HT6-receptor antagonists in Alzheimer\u2019s disease: an update","volume":"27","author":"Khoury","year":"2018","journal-title":"Expert Opin. Investig Drugs"},{"key":"10.1016\/j.arr.2021.101318_bib0450","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","article-title":"Inflammation as a central mechanism in alzheimer\u2019s disease","volume":"4","author":"Kinney","year":"2018","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.arr.2021.101318_bib0455","first-page":"11","article-title":"Gantenerumab reduces amyloid-\u03b2 plaques in patients with prodromal to moderate Alzheimer\u2019s disease: a PET substudy interim analysis","author":"Klein","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.arr.2021.101318_bib0460","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000486546","article-title":"A systematic review and meta-analysis of the effectiveness of acetylcholinesterase inhibitors and memantine in treating the cognitive symptoms of dementia","volume":"45","author":"Knight","year":"2018","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.arr.2021.101318_bib0465","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41582-018-0131-7","article-title":"Bad news and good news in AD, and how to reconcile them","volume":"15","author":"Knopman","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.arr.2021.101318_bib0470","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/1099-1077(200010)15:7<479::AID-HUP206>3.0.CO;2-5","article-title":"Quantitative EEG methods and measures in human psychopharmacological research","volume":"15","author":"Knott","year":"2000","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.arr.2021.101318_bib0475","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.neuroimage.2017.12.048","article-title":"Transcranial magnetic stimulation of the precuneus enhances memory and neural activity in prodromal Alzheimer\u2019s disease","volume":"169","author":"Koch","year":"2018","journal-title":"Neuroimage"},{"key":"10.1016\/j.arr.2021.101318_bib0480","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jamapsychiatry.2017.3292","article-title":"Extent of dorsolateral prefrontal cortex plasticity and its association with working memory in patients with alzheimer disease","volume":"74","author":"Kumar","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.arr.2021.101318_bib0485","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ejmech.2018.02.035","article-title":"Secretase inhibitors for the treatment of Alzheimer\u2019s disease: Long road ahead","volume":"148","author":"Kumar","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.arr.2021.101318_bib0490","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jmb.2011.11.047","article-title":"Structural basis of C-terminal beta-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer\u2019s disease","volume":"421","author":"La Porte","year":"2012","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.arr.2021.101318_bib0495","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrn2168","article-title":"Intracellular amyloid-beta in Alzheimer\u2019s disease","volume":"8","author":"LaFerla","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.arr.2021.101318_bib0500","article-title":"Deep brain stimulation for alzheimer\u2019s disease: tackling circuit dysfunction","author":"Lam","year":"2020","journal-title":"Neuromodulation"},{"key":"10.1016\/j.arr.2021.101318_bib0505","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1139\/jpn.0302","article-title":"Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer\u2019s disease","volume":"28","author":"Lanctot","year":"2003","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.arr.2021.101318_bib0510","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.trci.2017.05.003","article-title":"Ponezumab in mild-to-moderate Alzheimer\u2019s disease: randomized phase II PET-PIB study","volume":"3","author":"Landen","year":"2017","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.arr.2021.101318_bib0515","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/alzrt246","article-title":"Perspectives on future Alzheimer therapies: amyloid-beta protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer\u2019s disease","volume":"6","author":"Lannfelt","year":"2014","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.arr.2021.101318_bib0520","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3340\/jkns.2018.0180","article-title":"Magnetic resonance-guided focused ultrasound\u202f: current Status and future perspectives in thermal ablation and blood-brain barrier opening","volume":"62","author":"Lee","year":"2019","journal-title":"J Korean Neurosurg Soc"},{"key":"10.1016\/j.arr.2021.101318_bib0525","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3233\/JAD-180121","article-title":"Deep brain stimulation targeting the fornix for mild alzheimer dementia (the ADvance trial): a Two year follow-up including results of delayed activation","volume":"64","author":"Leoutsakos","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101318_bib0530","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00429-018-1779-x","article-title":"Chronic fornix deep brain stimulation in a transgenic Alzheimer\u2019s rat model reduces amyloid burden, inflammation, and neuronal loss","volume":"224","author":"Leplus","year":"2019","journal-title":"Brain Struct. Funct."},{"key":"10.1016\/j.arr.2021.101318_bib0535","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.3233\/JAD-200466","article-title":"Effects of chronic masitinib treatment in APPswe\/PSEN1dE9 transgenic mice modeling alzheimer\u2019s disease","volume":"76","author":"Li","year":"2020","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101318_bib0540","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1172\/JCI21746","article-title":"Amyloid at the cutting edge: activation of alpha-secretase prevents amyloidogenesis in an Alzheimer disease mouse model","volume":"113","author":"Lichtenthaler","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.arr.2021.101318_bib0545","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2174\/1567205053585846","article-title":"The molecular basis of memantine action in Alzheimer\u2019s disease and other neurologic disorders: low-affinity, uncompetitive antagonism","volume":"2","author":"Lipton","year":"2005","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.arr.2021.101318_bib0550","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-016-0181-2","article-title":"Safety and tolerability of BAN2401--a clinical study in Alzheimer\u2019s disease with a protofibril selective Abeta antibody","volume":"8","author":"Logovinsky","year":"2016","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.arr.2021.101318_bib0555","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","article-title":"Alzheimer disease: an update on pathobiology and treatment strategies","volume":"179","author":"Long","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.arr.2021.101318_bib0560","doi-asserted-by":"crossref","first-page":"P215","DOI":"10.1016\/j.jalz.2019.06.4562","article-title":"Preclinical development of TREM2 agonist antibody (AL002) in cynomolgus monkeys","volume":"15","author":"Long","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2021.101318_bib0565","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/bs.pmbts.2019.04.007","article-title":"Magnetoencephalography applied to the study of Alzheimer\u2019s disease","volume":"165","author":"Lopez-Sanz","year":"2019","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.arr.2021.101318_bib0570","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3233\/JAD-160017","article-title":"A phase II study of fornix deep brain stimulation in mild alzheimer\u2019s disease","volume":"54","author":"Lozano","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101318_bib0575","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/bs.irn.2020.03.014","article-title":"Tracking the potential involvement of metabolic disease in Alzheimer\u2019s disease-biomarkers and beyond","volume":"154","author":"Luchsinger","year":"2020","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.arr.2021.101318_bib0580","doi-asserted-by":"crossref","first-page":"P1623","DOI":"10.1016\/j.jalz.2018.07.213","article-title":"Elenbecestat, E2609, a BACE inhibitor: results from a phase 2 study in subjects with mild cognitive impairment and mild-to-moderate dementia due to Alzheimer\u2019s disease","volume":"14","author":"Lynch","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.arr.2021.101318_bib0585","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1474-4422(10)70119-8","article-title":"Alzheimer\u2019s disease: clinical trials and drug development","volume":"9","author":"Mangialasche","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.arr.2021.101318_bib0590","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.neuron.2020.02.024","article-title":"Modulation of human memory by deep brain stimulation of the entorhinal-hippocampal circuitry","volume":"106","author":"Mankin","year":"2020","journal-title":"Neuron"},{"key":"10.1016\/j.arr.2021.101318_bib0595","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1471-4159.2008.05396.x","article-title":"Etazolate, a neuroprotective drug linking GABA(a) receptor pharmacology to amyloid precursor protein processing","volume":"106","author":"Marcade","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.arr.2021.101318_bib0600","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13024-019-0325-5","article-title":"Neuroimaging biomarkers for alzheimer\u2019s disease","volume":"14","author":"Marquez","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.arr.2021.101318_bib0605","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1186\/s13104-018-3757-z","article-title":"Transcranial magnetic stimulation intervention in Alzheimer\u2019s disease: a research proposal for a randomized controlled trial","volume":"11","author":"Marron","year":"2018","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.arr.2021.101318_bib0610","doi-asserted-by":"crossref","first-page":"E1316","DOI":"10.1073\/pnas.1525466113","article-title":"The adaptive immune system restrains Alzheimer\u2019s disease pathogenesis by modulating microglial function","volume":"113","author":"Marsh","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.arr.2021.101318_bib0615","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1124\/jpet.109.152975","article-title":"Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer\u2019s disease","volume":"331","author":"Martone","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"256\u2013271","key":"10.1016\/j.arr.2021.101318_bib0620","first-page":"e222","article-title":"Multi-sensory gamma stimulation ameliorates alzheimer\u2019s-associated pathology and improves cognition","volume":"177","author":"Martorell","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.arr.2021.101318_bib0625","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/acn3.682","article-title":"Deep brain stimulation: potential for neuroprotection","volume":"6","author":"McKinnon","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.arr.2021.101318_bib0630","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1002\/cne.23415","article-title":"Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer\u2019s disease","volume":"521","author":"Mesulam","year":"2013","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.arr.2021.101318_bib0635","series-title":"Design of the First-in-Human Study of IONIS-MAPTRx, a Tau-Lowering Antisense Oligonucleotide, in Patients With Alzheimer Disease (S2. 006)","author":"Mignon","year":"2018"},{"key":"10.1016\/j.arr.2021.101318_bib0640","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419888819","article-title":"Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer\u2019s disease","volume":"12","author":"Mila-Aloma","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.arr.2021.101318_bib0645","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1016\/j.jacr.2020.01.040","article-title":"ACR appropriateness criteria(R) dementia","volume":"17","author":"Moonis","year":"2020","journal-title":"J. Am. Coll. Radiol."},{"key":"10.1016\/j.arr.2021.101318_bib0650","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jalz.2019.03.007","article-title":"Inflammatory biomarkers in Alzheimer\u2019s disease plasma","volume":"15","author":"Morgan","year":"2019","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.arr.2021.101318_bib0655","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3233\/JAD-160742","article-title":"Levetiracetam alters oscillatory connectivity in alzheimer\u2019s disease","volume":"58","author":"Musaeus","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101318_bib0660","doi-asserted-by":"crossref","first-page":"S574","DOI":"10.1016\/j.jalz.2010.05.1958","article-title":"E2012, a novel gamma-secretase modulator, decreases plasma amyloid-beta (a\u03b2) levels in humans","volume":"6","author":"Nagy","year":"2010","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.arr.2021.101318_bib0665","series-title":"Molecular Neuropharmacology: A Foundation for Clinical Neuroscience","author":"Nestler","year":"2015"},{"key":"10.1016\/j.arr.2021.101318_bib0670","first-page":"10","article-title":"The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer\u2019s disease","author":"Neumann","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.arr.2021.101318_bib0675","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.neuron.2013.03.006","article-title":"Auditory closed-loop stimulation of the sleep slow oscillation enhances memory","volume":"78","author":"Ngo","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.arr.2021.101318_bib0680","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/brain\/awz142","article-title":"Persistent neuropathological effects 14 years following amyloid-beta immunization in Alzheimer\u2019s disease","volume":"142","author":"Nicoll","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.arr.2021.101318_bib0685","doi-asserted-by":"crossref","first-page":"E8788","DOI":"10.1073\/pnas.1714175114","article-title":"RIPK1 mediates a disease-associated microglial response in Alzheimer\u2019s disease","volume":"114","author":"Ofengeim","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.arr.2021.101318_bib0690","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.arr.2021.101318_bib0695","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s11481-016-9722-5","article-title":"Safety and efficacy of anti-amyloid-beta immunotherapy in alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"12","author":"Penninkilampi","year":"2017","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.arr.2021.101318_bib0700","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1111\/bph.14585","article-title":"Mitochondrial dysfunction in Alzheimer\u2019s disease: role in pathogenesis and novel therapeutic opportunities","volume":"176","author":"Perez Ortiz","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.arr.2021.101318_bib0705","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3389\/fnagi.2013.00058","article-title":"Integrative EEG biomarkers predict progression to Alzheimer\u2019s disease at the MCI stage","volume":"5","author":"Poil","year":"2013","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.arr.2021.101318_bib0710","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.3171\/2020.4.FOCUS20167","article-title":"Clinical applications of neurochemical and electrophysiological measurements for closed-loop neurostimulation","volume":"49","author":"Price","year":"2020","journal-title":"Neurosurg. Focus"},{"key":"10.1016\/j.arr.2021.101318_bib0715","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1080\/13543784.2017.1364360","article-title":"Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer\u2019s disease","volume":"26","author":"Prickaerts","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.arr.2021.101318_bib0720","doi-asserted-by":"crossref","first-page":"e778","DOI":"10.1212\/WNL.0000000000007967","article-title":"Cognitive heterogeneity in probable Alzheimer disease: clinical and neuropathologic features","volume":"93","author":"Qiu","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2021.101318_bib0725","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s00702-016-1606-6","article-title":"Repetitive transcranial magnetic stimulation (rTMS) combined with cognitive training is a safe and effective modality for the treatment of Alzheimer\u2019s disease: clinical experience","volume":"123","author":"Rabey","year":"2016","journal-title":"J. Neural. Transm. (Vienna)"},{"key":"10.1016\/j.arr.2021.101318_bib0730","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.clinph.2020.03.003","article-title":"Early diagnosis of Alzheimer\u2019s disease: the role of biomarkers including advanced EEG signal analysis. Report from the IFCN-sponsored panel of experts","volume":"131","author":"Rossini","year":"2020","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.arr.2021.101318_bib0735","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.jalz.2019.08.197","article-title":"Effects of a combined transcranial magnetic stimulation (TMS) and cognitive training intervention in patients with Alzheimer\u2019s disease","volume":"16","author":"Sabbagh","year":"2020","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.arr.2021.101318_bib0740","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/s41386-018-0168-8","article-title":"TAK-071, a novel M1 positive allosteric modulator with low cooperativity, improves cognitive function in rodents with few cholinergic side effects","volume":"44","author":"Sako","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.arr.2021.101318_bib0745","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2021.101318_bib0750","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13195-018-0424-5","article-title":"Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer\u2019s disease (BLAZE)","volume":"10","author":"Salloway","year":"2018","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.arr.2021.101318_bib0755","article-title":"Past, present, and future of Non-invasive brain stimulation approaches to treat cognitive impairment in neurodegenerative diseases: time for a comprehensive critical review","volume":"12","author":"Sanches","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.arr.2021.101318_bib0760","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/acn3.549","article-title":"An exploratory clinical study of p38alpha kinase inhibition in Alzheimer\u2019s disease","volume":"5","author":"Scheltens","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.arr.2021.101318_bib0765","series-title":"Clinical Trials on Alzheimer\u2019s Disease (CTAD)","article-title":"Efficacy and safety results of REVERSE-SD, phase-2b clinical study of the selective p38\u03b1 kinase inhibitor neflamapimod in early-stage Alzheimer\u2019s disease (AD)","author":"Scheltens","year":"2019"},{"key":"10.1016\/j.arr.2021.101318_bib0770","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s12603-009-0070-5","article-title":"Development of AFFITOPE vaccines for Alzheimer\u2019s disease (AD)--from concept to clinical testing","volume":"13","author":"Schneeberger","year":"2009","journal-title":"J. Nutr. Health Aging"},{"key":"10.1016\/j.arr.2021.101318_bib0775","first-page":"103","article-title":"Results from a phase II study to assess the clinical and immunological activity of AFFITOPE(R) AD02 in patients with early alzheimer\u2019s disease","volume":"2","author":"Schneeberger","year":"2015","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101318_bib0780","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41582-019-0205-1","article-title":"Alzheimer disease and aducanumab: adjusting our approach","volume":"15","author":"Selkoe","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.arr.2021.101318_bib0785","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.tins.2018.03.015","article-title":"Fornical closed-loop stimulation for alzheimer\u2019s disease","volume":"41","author":"Senova","year":"2018","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.arr.2021.101318_bib0790","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces Abeta plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.arr.2021.101318_bib0795","article-title":"Regional cerebral blood flow in mild cognitive impairment and alzheimer\u2019s disease measured with arterial spin labeling magnetic resonance imaging","volume":"2017","author":"Sierra-Marcos","year":"2017","journal-title":"Int. J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101318_bib0800","doi-asserted-by":"crossref","first-page":"P418","DOI":"10.1016\/j.jalz.2009.04.925","article-title":"Exebryl-1: a novel small molecule currently in human clinical trials as a disease-modifying drug for the treatment of Alzheimer\u2019s disease","volume":"5","author":"Snow","year":"2009","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.arr.2021.101318_bib0805","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13024-017-0222-8","article-title":"The Trojan horse - neuroinflammatory impact of T cells in neurodegenerative diseases","volume":"12","author":"Sommer","year":"2017","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.arr.2021.101318_bib0810","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/nrneurol.2011.165","article-title":"Alzheimer disease: statins in the treatment of Alzheimer disease","volume":"7","author":"Sparks","year":"2011","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.arr.2021.101318_bib0815","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","article-title":"Amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with bapineuzumab: a retrospective analysis","volume":"11","author":"Sperling","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.arr.2021.101318_bib0820","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1017\/S1092852918001360","article-title":"New hope for Alzheimer\u2019s dementia as prospects for disease modification fade: symptomatic treatments for agitation and psychosis","volume":"23","author":"Stahl","year":"2018","journal-title":"CNS Spectr."},{"key":"10.1016\/j.arr.2021.101318_bib0825","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.bcp.2015.07.006","article-title":"Concentration-response relationship of the alpha7 nicotinic acetylcholine receptor agonist FRM-17874 across multiple in vitro and in vivo assays","volume":"97","author":"Stoiljkovic","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.arr.2021.101318_bib0830","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1093\/cercor\/bhy140","article-title":"Altered cortical and hippocampal excitability in TgF344-AD rats modeling alzheimer\u2019s disease pathology","volume":"29","author":"Stoiljkovic","year":"2019","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.arr.2021.101318_bib0835","doi-asserted-by":"crossref","first-page":"466","DOI":"10.15252\/emmm.201506123","article-title":"sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer\u2019s disease and associate with neuronal injury markers","volume":"8","author":"Suarez-Calvet","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.arr.2021.101318_bib0840","doi-asserted-by":"crossref","first-page":"17627","DOI":"10.1038\/s41598-020-74790-7","article-title":"EEG microstate complexity for aiding early diagnosis of Alzheimer\u2019s disease","volume":"10","author":"Tait","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2021.101318_bib0845","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.trci.2018.02.002","volume":"4","author":"Tariot","year":"2018","journal-title":"Alzheimers Dement. (N Y)"},{"key":"10.1016\/j.arr.2021.101318_bib0850","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4155\/tde-2019-0035","article-title":"Industry update: the latest developments in the field of therapeutic delivery, April 2019","volume":"10","author":"Timmins","year":"2019","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.arr.2021.101318_bib0855","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1080\/14712598.2017.1322578","article-title":"Daratumumab for the treatment of multiple myeloma","volume":"17","author":"Touzeau","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.arr.2021.101318_bib0860","doi-asserted-by":"crossref","DOI":"10.1088\/1741-2560\/12\/6\/066017","article-title":"Neural dynamics during repetitive visual stimulation","volume":"12","author":"Tsoneva","year":"2015","journal-title":"J. Neural Eng."},{"key":"10.1016\/j.arr.2021.101318_bib0865","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3233\/JAD-190888","article-title":"Low-frequency repetitive transcranial magnetic stimulation of the right dorsolateral prefrontal cortex enhances recognition memory in alzheimer\u2019s disease","volume":"72","author":"Turriziani","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101318_bib0870","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.biopsych.2017.08.010","article-title":"Anti-amyloid-beta monoclonal antibodies for alzheimer\u2019s disease: pitfalls and promise","volume":"83","author":"van Dyck","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.arr.2021.101318_bib0875","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jalz.2018.08.005","article-title":"Understanding disease progression and improving alzheimer\u2019s disease clinical trials: recent highlights from the alzheimer\u2019s disease neuroimaging initiative","volume":"15","author":"Veitch","year":"2019","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.arr.2021.101318_bib0880","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.pneurobio.2009.11.005","article-title":"Steady-state visually evoked potentials: focus on essential paradigms and future perspectives","volume":"90","author":"Vialatte","year":"2010","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.arr.2021.101318_bib0885","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/s41467-018-02928-3","article-title":"Direct effects of transcranial electric stimulation on brain circuits in rats and humans","volume":"9","author":"Voroslakos","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.arr.2021.101318_bib0890","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.trci.2018.03.004","article-title":"Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer\u2019s disease","volume":"4","author":"Voss","year":"2018","journal-title":"Alzheimers Dement. (N Y)"},{"key":"10.1016\/j.arr.2021.101318_bib0895","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1474-4422(17)30044-3","article-title":"Epileptic activity in Alzheimer\u2019s disease: causes and clinical relevance","volume":"16","author":"Vossel","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.arr.2021.101318_bib0900","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1517\/13543784.2015.1001490","article-title":"Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer\u2019s disease","volume":"24","author":"Walker","year":"2015","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.arr.2021.101318_bib0905","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41422-019-0216-x","article-title":"Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer\u2019s disease progression","volume":"29","author":"Wang","year":"2019","journal-title":"Cell Res."},{"key":"10.1016\/j.arr.2021.101318_bib0910","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00415-019-09644-y","article-title":"Repetitive transcranial magnetic stimulation for cognitive impairment in Alzheimer\u2019s disease: a meta-analysis of randomized controlled trials","volume":"267","author":"Wang","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.arr.2021.101318_bib0915","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1523\/JNEUROSCI.1427-19.2019","article-title":"Stimulation augments spike sequence replay and memory consolidation during slow-wave sleep","volume":"40","author":"Wei","year":"2020","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2021.101318_bib0920","first-page":"7","article-title":"Transcranial magnetic stimulation in alzheimer\u2019s disease: are We ready?","author":"Weiler","year":"2020","journal-title":"eNeuro"},{"key":"10.1016\/j.arr.2021.101318_bib0925","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s40478-019-0795-2","article-title":"Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer\u2019s disease","volume":"7","author":"Whelan","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.arr.2021.101318_bib0930","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3233\/JAD-2008-15404","article-title":"Anti-amyloid-beta immunotherapy in Alzheimer\u2019s disease: relevance of transgenic mouse studies to clinical trials","volume":"15","author":"Wilcock","year":"2008","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101318_bib0935","doi-asserted-by":"crossref","first-page":"11246","DOI":"10.1523\/JNEUROSCI.2488-10.2010","article-title":"Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses","volume":"30","author":"Xia","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2021.101318_bib0940","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/ageing\/afx045","article-title":"Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer\u2019s disease: a phase II multicenter randomised controlled trial","volume":"46","author":"Xiao","year":"2017","journal-title":"Age Ageing"},{"key":"10.1016\/j.arr.2021.101318_bib0945","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3233\/JAD-180450","article-title":"Effectiveness of a personalized brain-computer interface system for cognitive training in healthy elderly: a randomized controlled trial","volume":"66","author":"Yeo","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101318_bib0950","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jpsychires.2020.02.017","article-title":"Functional near-infrared spectroscopy reveals decreased resting oxygenation levels and task-related oxygenation changes in mild cognitive impairment and dementia: a systematic review","volume":"124","author":"Yeung","year":"2020","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.arr.2021.101318_bib0955","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13195-020-00612-7","article-title":"Imaging biomarkers in neurodegeneration: current and future practices","volume":"12","author":"Young","year":"2020","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.arr.2021.101318_bib0960","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/s41598-018-19641-2","article-title":"Cromolyn reduces levels of the alzheimer\u2019s disease-associated amyloid beta-protein by promoting microglial phagocytosis","volume":"8","author":"Zhang","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2021.101318_bib0965","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.trci.2017.07.002","article-title":"Gamma rhythm low field magnetic stimulation alleviates neuropathologic changes and rescues memory and cognitive impairments in a mouse model of Alzheimer\u2019s disease","volume":"3","author":"Zhen","year":"2017","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.arr.2021.101318_bib0970","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.biopsych.2018.04.022","article-title":"Consequences of pharmacological BACE inhibition on synaptic structure and function","volume":"84","author":"Zhu","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.arr.2021.101318_bib0975","doi-asserted-by":"crossref","first-page":"6309","DOI":"10.1038\/s41598-019-42693-x","article-title":"Pulsed near infrared transcranial and intranasal photobiomodulation significantly modulates neural oscillations: a pilot exploratory study","volume":"9","author":"Zomorrodi","year":"2019","journal-title":"Sci. Rep."}],"container-title":["Ageing Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163721000659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163721000659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:01:27Z","timestamp":1778619687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568163721000659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":195,"alternative-id":["S1568163721000659"],"URL":"https:\/\/doi.org\/10.1016\/j.arr.2021.101318","relation":{},"ISSN":["1568-1637"],"issn-type":[{"value":"1568-1637","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapy for Alzheimer\u2019s disease: Missing targets and functional markers?","name":"articletitle","label":"Article Title"},{"value":"Ageing Research Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arr.2021.101318","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101318"}}